Myeloablative_combination_chemotherapy_without_total_body_irradiation_for_neuroblastoma._Myeloablative_treatment_intensification_in_25_patients_diagnosed_when_older_than_12_months_of_age_with_stage_IV_neuroblastoma_included_sequential_delivery_of_cisplatin_120_mg/m2_x_1,_hyperfractionated_radiation_(2,100_cGy)_to_the_primary_site_and_adjacent_lymph_nodes,_carmustine_(BCNU)_200_mg/m2_x_1,_melphalan_60_mg/m2/d_x_3_(n_=_13)_or_thiotepa_300_mg/m2/d_x_3._(n_=_12),_and_etoposide_(VP_16)_300_mg/m2/d_x_3._Seventy-two_hours_after_the_last_dose_of_VP_16,_histologically_tumor-free_and_4-hydroperoxycyclophosphamide_(4-HC;_100_mumol/L)-purged_autologous_bone_marrow_(ABMT)_was_infused._Acute_toxicities_included_grade_3_to_4_oral_mucositis,_grade_1_to_2_diarrhea,_and_fevers._No_patient_required_infusion_of_unpurged_reserve_autografts._At_ABMT,_16_patients_(group_I)_were_progression-free_6.5_months_to_14_months_(median,_9_months)_from_diagnosis:_seven_remain_progression-free_20_months_to_46_months_(median,_39_months)_off_therapy,_six_relapsed_4_months_to_17_months_post-ABMT,_and_three_died_of_toxicity_(candidiasis,_metabolic_derangement,_and_venoocclusive_disease_VOD)._The_event-free_survival_of_group_I_patients_is_44%_at_24_months_post-ABMT._Nine_patients_(group_II)_were_in_second_remission_at_ABMT,_including_three_who_had_relapsed_after_other_transplant_procedures:_two_are_progression-free_24_months_and_41_months_off_therapy,_four_relapsed_3_months_to_12_months_post-ABMT,_and_three_died_of_toxicity_(aspergillosis,_hemorrhagic_cystitis,_VOD)._Only_one_of_10_relapses_involved_a_primary_site,_suggesting_a_beneficial_effect_of_local_radiation._In_terms_of_survival_or_toxicity,_an_advantage_for_melphalan_or_thiotepa_was_not_evident._Regimens_such_as_this_may_prolong_the_survival_of_selected_patients_with_poor-risk_neuroblastoma,_but_concerns_over_late_relapses_and_toxicity_mandate_continuing_efforts_to_devise_alternative,_less_risky,_and_more_clearly_beneficial_approaches_for_definitive_ablation_of_neuroblastoma.